CN1138755C - 作为药物的环状氨基酸及其衍生物 - Google Patents

作为药物的环状氨基酸及其衍生物 Download PDF

Info

Publication number
CN1138755C
CN1138755C CNB98810346XA CN98810346A CN1138755C CN 1138755 C CN1138755 C CN 1138755C CN B98810346X A CNB98810346X A CN B98810346XA CN 98810346 A CN98810346 A CN 98810346A CN 1138755 C CN1138755 C CN 1138755C
Authority
CN
China
Prior art keywords
aminomethyl
acetic acid
cyclopentyl
compound
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB98810346XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1276784A (zh
Inventor
Js
J·S·布莱恩斯
D·C·豪威尔
A·J·索尔普
D·J·乌斯特罗
���ڶ���
P－W·于恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of CN1276784A publication Critical patent/CN1276784A/zh
Application granted granted Critical
Publication of CN1138755C publication Critical patent/CN1138755C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/50—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C205/51—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/50—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C205/53—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/385—Saturated compounds containing a keto group being part of a ring
    • C07C49/417—Saturated compounds containing a keto group being part of a ring polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/608—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a ring other than a six-membered aromatic ring in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/612—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/50—Spiro compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB98810346XA 1997-10-27 1998-09-23 作为药物的环状氨基酸及其衍生物 Expired - Fee Related CN1138755C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6364497P 1997-10-27 1997-10-27
US60/063,644 1997-10-27
US9768598P 1998-08-24 1998-08-24
US60/097,685 1998-08-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB2003101209321A Division CN1303059C (zh) 1997-10-27 1998-09-23 作为药物的环状氨基酸及其衍生物

Publications (2)

Publication Number Publication Date
CN1276784A CN1276784A (zh) 2000-12-13
CN1138755C true CN1138755C (zh) 2004-02-18

Family

ID=26743626

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB98810346XA Expired - Fee Related CN1138755C (zh) 1997-10-27 1998-09-23 作为药物的环状氨基酸及其衍生物
CNB2003101209321A Expired - Fee Related CN1303059C (zh) 1997-10-27 1998-09-23 作为药物的环状氨基酸及其衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB2003101209321A Expired - Fee Related CN1303059C (zh) 1997-10-27 1998-09-23 作为药物的环状氨基酸及其衍生物

Country Status (30)

Country Link
US (3) US6635673B1 (enExample)
EP (1) EP1032555B1 (enExample)
JP (2) JP3756761B2 (enExample)
KR (1) KR100589066B1 (enExample)
CN (2) CN1138755C (enExample)
AR (1) AR013726A1 (enExample)
AT (1) ATE323067T1 (enExample)
AU (1) AU755800B2 (enExample)
BR (1) BR9813284B1 (enExample)
CA (1) CA2303244C (enExample)
CO (1) CO5280097A1 (enExample)
CU (1) CU23048A3 (enExample)
CY (1) CY1105062T1 (enExample)
DE (1) DE69834204T2 (enExample)
DK (1) DK1032555T3 (enExample)
ES (1) ES2260850T3 (enExample)
GE (1) GEP20094817B (enExample)
HU (1) HUP0004310A3 (enExample)
IL (1) IL134732A (enExample)
IS (1) IS2489B (enExample)
NO (1) NO327671B1 (enExample)
NZ (1) NZ503651A (enExample)
PE (1) PE122799A1 (enExample)
PL (2) PL199794B1 (enExample)
PT (1) PT1032555E (enExample)
SI (1) SI1032555T1 (enExample)
TR (1) TR200001170T2 (enExample)
UY (1) UY25223A1 (enExample)
WO (1) WO1999021824A1 (enExample)
ZA (1) ZA989740B (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU225502B1 (en) * 1998-12-29 2007-01-29 Richter Gedeon Vegyeszet Process for producing 1-(amino-metyl)-cyclohexene-acetic-acid and intermediates
JP2003500466A (ja) * 1999-05-26 2003-01-07 ワーナー−ランバート・カンパニー 医薬としての融合多環式アミノ酸
US6642398B2 (en) 1999-06-10 2003-11-04 Warner-Lambert Company Mono-and disubstituted 3-propyl gamma-aminobutyric acids
CZ300834B6 (cs) * 1999-06-10 2009-08-19 Warner-Lambert Company Llc Mono- a disubstituované kyseliny 3-propyl-gamma-aminomáselné
EP1840117A1 (en) * 1999-06-10 2007-10-03 Warner-Lambert Company LLC Mono- and disubstituted 3-propyl gamma-aminobutyric acids
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
HN2000000224A (es) 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
BR0016201A (pt) * 1999-12-08 2002-08-13 Warner Lambert Co Método para a sìntese estereosseletiva de aminoácidos cìclicos
US6864390B2 (en) 1999-12-08 2005-03-08 Warner-Lambert Company Method for the stereoselective synthesis of cyclic amino acids
GB2362646A (en) * 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
NZ522480A (en) * 2000-06-26 2005-06-24 Warner Lambert Co Gabapentin analogues for sleep disorders
GB2364049A (en) 2000-06-28 2002-01-16 Warner Lambert Co Cyclic ketones and their use in the synthesis of amino acids
WO2002028881A1 (en) 2000-10-06 2002-04-11 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
AU2002230398A1 (en) 2000-10-06 2002-04-29 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
EP1226820A1 (en) 2001-01-26 2002-07-31 Warner-Lambert Company Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
CA2444053C (en) * 2001-04-19 2008-06-17 Warner-Lambert Company Llc Fused bicyclic or tricyclic amino acids
GB2374595A (en) * 2001-04-19 2002-10-23 Warner Lambert Co Fused bicyclic or tricyclic amino acids
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AU2002310409C1 (en) 2001-06-11 2008-04-17 Xenoport, Inc. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP1412324A4 (en) 2001-06-11 2004-09-29 Xenoport Inc AMINO ACID CONJUGATES THAT RESULT IN GABA ANALOGA LASTING SYSTEMIC CONCENTRATIONS
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
WO2003080588A1 (en) 2002-03-20 2003-10-02 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
WO2003099338A2 (en) 2002-05-17 2003-12-04 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
GB0223072D0 (en) 2002-10-04 2002-11-13 Pfizer Ltd Cyclic nitromethyl acetic acid derivatives
US7018818B2 (en) 2002-10-04 2006-03-28 Pfizer Inc. Intermediates in the preparation of therapeutic fused bicyclic amino acids
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
AU2003297927A1 (en) 2002-12-11 2004-06-30 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
PT1572173E (pt) 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
EP2172197A1 (en) 2002-12-13 2010-04-07 Warner-Lambert Company LLC Octanoic acid derivative to treat fibromyalgia and other pains
AU2003283718A1 (en) * 2002-12-13 2004-07-09 Warner-Lambert Company Llc Gabapentin analogues for fibromyalgia and other related disorders
WO2005002585A1 (en) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
CA2537837A1 (en) 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
ATE449633T1 (de) 2003-09-12 2009-12-15 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
CA2538802C (en) 2003-09-17 2015-01-27 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
CA2541752C (en) 2003-10-14 2012-01-03 Xenoport, Inc. Crystalline form of gamma-aminobutyric acid analog
PT1691811E (pt) 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
UA82292C2 (uk) * 2004-04-14 2008-03-25 Пфайзер Продактс Инк. Спосіб стереоселективного біоперетворення аліфатичних динітрилів в ціанокарбонові кислоти (варіанти)
EP1811986B1 (en) 2004-11-04 2014-03-26 XenoPort, Inc. Gabapentin prodrug sustained release oral dosage forms
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
WO2007010387A2 (en) * 2005-07-18 2007-01-25 Pharmacia & Upjohn Company Llc Stereoselective synthesis of 3,4-disubstituted cyclopentanones and related compounds
EP1820502A1 (en) 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising azolylcarbinol compounds
CA2640402C (en) * 2006-03-06 2012-01-03 Pfizer Products Inc. Alpha-2-delta ligands for non-restorative sleep
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
CN102058885B (zh) 2006-12-22 2013-04-10 瑞蔻达蒂爱尔兰有限公司 采用α2δ配体和NSAID的下泌尿道疾病的联合治疗
WO2008155619A2 (en) * 2007-06-21 2008-12-24 Pfizer Inc. Preparation of optically-active cyclic amino acids
KR101335784B1 (ko) 2007-09-28 2013-12-05 다이이찌 산쿄 가부시키가이샤 2 고리성 γ-아미노산 유도체
WO2009094563A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
CA2710538A1 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of a (3s)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
ES2589915T3 (es) 2008-10-08 2016-11-17 Xgene Pharmaceutical Inc Conjugados de GABA y métodos de utilización de los mismos
WO2010110361A1 (ja) 2009-03-26 2010-09-30 第一三共株式会社 二環性γ－アミノ酸誘導体の製造方法
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
BR112013031360B1 (pt) 2011-06-08 2022-01-25 Daiichi Sankyo Company, Limited Método para produzir um composto
ES2649968T3 (es) 2011-06-08 2018-01-16 Daiichi Sankyo Company, Limited Procedimiento de producción de un compuesto bicíclico vía transposición de Claisen
HUE040225T2 (hu) 2011-12-15 2019-02-28 Daiichi Sankyo Co Ltd Eljárás biciklikus vegyület optikai elválasztására aszimmetrikus katalizátort felhasználva
HUE033397T2 (en) 2012-04-10 2017-12-28 Daiichi Sankyo Co Ltd A method for the optical separation of bicyclic compounds by an enzyme
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
HUE047629T2 (hu) 2013-01-28 2020-05-28 Lopez Hector L Eljárások ß-alanin tolerancia, farmakodinamika és hatékonyság javítására és azok alkalmazása
TWI635071B (zh) 2013-07-08 2018-09-11 第一三共股份有限公司 光學活性二環γ－胺基酸衍生物及其製造方法
SG11201604480PA (en) 2013-12-17 2016-07-28 Esteve Labor Dr SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
MX2016007286A (es) 2013-12-17 2016-08-04 Esteve Labor Dr Combinaciones de gabapentinoides y ligandos de receptores sigma.
JP7441181B2 (ja) 2018-05-14 2024-02-29 エックスジーン ファーマシューティカル インク． ナプロキセンとプレガバリンの１－（アシルオキシ）－アルキルカルバメート薬品複合体の結晶形態
MX2021000403A (es) 2018-07-12 2021-03-25 Sichuan Haisco Pharmaceutical Co Ltd Composicion de derivados de aminoacido gamma triciclico fusionados y la preparacion de la misma.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2611690A1 (de) 1976-03-19 1977-09-22 Goedecke Ag Cyclische sulfonyloxyimide
CA1085420A (en) 1977-03-24 1980-09-09 Johannes Hartenstein 1-aminomethyl-1-cycloalkane-acetic acid
US5132451A (en) 1989-08-25 1992-07-21 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
US5319135A (en) 1989-08-25 1994-06-07 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
DE3928184A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte
US5084479A (en) 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
EP0458751A1 (en) 1990-05-25 1991-11-27 Warner-Lambert Company Delivery system for cyclic amino acids with improved taste, texture and compressibility
US5025035A (en) 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
EP0482834B1 (en) 1990-10-20 1996-01-17 Takasago International Corporation Process for producing alpha-hydroxyketones
AU2807192A (en) 1991-10-02 1993-05-03 Smithkline Beecham Corporation Cyclopentane and cyclopentene derivatives with antiallergic antiinflammatory and tumor necrosis factor inhibiting activity
US5631291A (en) 1992-05-29 1997-05-20 Bayer Aktiengesellschaft Cyclopentane- and -pentene-β-amino acids
DE4400749A1 (de) 1994-01-13 1995-07-20 Bayer Ag Neues hochenantioselektives Verfahren zur Herstellung von enantiomerenreinen Cyclopentan- und -penten-beta-Aminosäuren
CA2193384C (en) 1994-07-27 2002-03-19 Geoffrey Neil Woodruff Use of gabapentin in the treatment of anxiety and panic
US5510381A (en) 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
DK0888286T3 (da) * 1996-03-14 2002-02-18 Warner Lambert Co Nye substituerede cykliske aminosyrer som farmaceutiske midler
HRP980342A2 (en) 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
US9858641B2 (en) * 2014-12-15 2018-01-02 International Business Machines Corporation Representing a system using viewpoints
US9419648B1 (en) * 2015-09-18 2016-08-16 Intel Corporation Supporting data compression using match scoring

Also Published As

Publication number Publication date
DK1032555T3 (da) 2006-07-17
JP2006096758A (ja) 2006-04-13
IL134732A0 (en) 2001-04-30
CA2303244C (en) 2005-12-06
EP1032555A1 (en) 2000-09-06
TR200001170T2 (tr) 2000-10-23
IS5395A (is) 2000-03-03
US6921835B2 (en) 2005-07-26
JP2001521020A (ja) 2001-11-06
GEP20094817B (en) 2009-11-10
DE69834204D1 (de) 2006-05-24
HUP0004310A3 (en) 2001-11-28
NO20002118L (no) 2000-04-26
JP3756761B2 (ja) 2006-03-15
AU755800B2 (en) 2002-12-19
UY25223A1 (es) 2001-08-27
HUP0004310A2 (hu) 2001-04-28
HK1030768A1 (en) 2001-05-18
CU23048A3 (es) 2005-06-24
IL134732A (en) 2004-03-28
ATE323067T1 (de) 2006-04-15
BR9813284A (pt) 2000-08-22
CA2303244A1 (en) 1999-05-06
WO1999021824A1 (en) 1999-05-06
ES2260850T3 (es) 2006-11-01
US6635673B1 (en) 2003-10-21
CN1276784A (zh) 2000-12-13
PT1032555E (pt) 2006-07-31
CN1500773A (zh) 2004-06-02
CN1303059C (zh) 2007-03-07
US20050159487A1 (en) 2005-07-21
US20030220397A1 (en) 2003-11-27
NO327671B1 (no) 2009-09-07
CO5280097A1 (es) 2003-05-30
IS2489B (is) 2009-01-15
AR013726A1 (es) 2001-01-10
US7122678B2 (en) 2006-10-17
KR20010031440A (ko) 2001-04-16
KR100589066B1 (ko) 2006-06-13
PL340285A1 (en) 2001-01-29
PL199794B1 (pl) 2008-10-31
SI1032555T1 (sl) 2006-08-31
HK1061841A1 (en) 2004-10-08
CY1105062T1 (el) 2009-11-04
BR9813284B1 (pt) 2012-08-21
EP1032555B1 (en) 2006-04-12
NO20002118D0 (no) 2000-04-26
DE69834204T2 (de) 2007-03-29
PL199500B1 (pl) 2008-09-30
NZ503651A (en) 2002-09-27
AU9663898A (en) 1999-05-17
PE122799A1 (es) 1999-12-19
ZA989740B (en) 1999-04-25
JP4263717B2 (ja) 2009-05-13

Similar Documents

Publication Publication Date Title
CN1276784A (zh) 作为药物的环状氨基酸及其生物
HK1049826A1 (en) Bicyclic amino acids as pharmaceutical agents
CN87107371A (zh) 螺-取代的戊二酰胺利尿剂
CN1279674A (zh) 1－取代－1－氨基甲基－环烷衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途
CN1145897A (zh) 新的芳基(烷基)丙基酰胺，制备此类酰胺的方法和含此类酰胺的药物组合物
CN1118467C (zh) 1,3,8－三氮杂螺[4,5]癸－4－酮衍生物
CN1137889C (zh) 新三环酰胺化合物,其制法和含它们的药物组合物
CN1626069A (zh) 支链氨基酸依赖性氨基转移酶的抑制剂及其在治疗糖尿病性视网膜病中的应用
CN1135480A (zh) 新烷基化杂环化合物，这类化合物的制备方法以及含这类化合物的药物组合物
CN1794985A (zh) 氮杂双环衍生物作为毒蕈碱受体拮抗剂
CN1407967A (zh) 立体选择性地合成环状氨基酸的方法
CN1064349C (zh) 新型三环酰胺、其制备方法及其药物组合物
CN1079465A (zh) 吲哚类
CN88101674A (zh) 色酮衍生物
CN1216856C (zh) 具有亚环烷基链的新环状化合物,其制备方法和含有它们的药物组合物
CN1145617A (zh) 吲哚衍生物及含它们的药物
CN1202103A (zh) 兴奋性的氨基酸受体拮抗剂
CN1835926A (zh) 非肽类取代螺苯并氮杂䓬衍生物的制备方法
CN1199960C (zh) 新的沉香呋喃衍生物,它们的制备方法,含它们的药物组合物及它们作为药物的用途
CN1345317A (zh) (1－苯甲酰甲基－3－苯基－3－哌啶基乙基)哌啶衍生物,制备它们的方法以及包含它们的药物组合物
HK1030768B (en) Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
CN1753898A (zh) 六氢呋喃并呋喃醇衍生物的制备方法、其中间体及其制备方法
HK1061841B (en) Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
CN1177842C (zh) 新的沉香呋喃衍生物、它们的药物组合物及它们制备药物的用途
CN1898224A (zh) 二环[3.1.0]己烷衍生物的制备方法及其中间体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CI01 Publication of corrected invention patent application

Correction item: Denomination of Invention

Correct: Cyclic amino acids and derivatives thereof

False: A cyclic amino acid and its organism as a drug

Number: 50

Page: 121

Volume: 16

CI02 Correction of invention patent application

Correction item: Denomination of Invention

Correct: Cyclic amino acids and derivatives thereof

False: A cyclic amino acid and its organism as a drug

Number: 50

Page: The title page

Volume: 16

COR Change of bibliographic data

Free format text: CORRECT: INVENTION NAME; FROM: CYCLIC AMINO ACID AND LIVING BEINGS AS THE MEDICINE TO: CYCLIC AMINOACID AND DERIVANT AS THE MEDICINE

ERR Gazette correction

Free format text: CORRECT: INVENTION NAME; FROM: CYCLIC AMINO ACID AND LIVING BEINGS AS THE MEDICINE TO: CYCLIC AMINOACID AND DERIVANT AS THE MEDICINE

C14 Grant of patent or utility model
GR01 Patent grant
CI01 Publication of corrected invention patent application

Correction item: Priority

Correct: 1997.10.27 US 60/063,644|1997.08.24 US 60/097,685

False: 1997.10.27 US 60/063,644

Number: 7

Page: 394

Volume: 20

CI03 Correction of invention patent

Correction item: Priority

Correct: 1997.10.27 US 60/063,644|1997.08.24 US 60/097,685

False: 1997.10.27 US 60/063,644

Number: 7

Page: The title page

Volume: 20

COR Change of bibliographic data

Free format text: CORRECT: PRIORITY; FROM: 1997.10.27 US 60/063,644 TO: 1997.10.27 US 60/063,644 1997.8.24 US 60/097,685

ERR Gazette correction

Free format text: CORRECT: PRIORITY; FROM: 1997.10.27 US 60/063,644 TO: 1997.10.27 US 60/063,644 1997.8.24 US 60/097,685

CI01 Publication of corrected invention patent application

Correction item: Priority

Correct: 1997.10.27 US 60/063,644|1998.08.24 US 097,685

False: 1997.10.27 US 60/063,644

Number: 7

Volume: 20

CI03 Correction of invention patent

Correction item: Priority

Correct: 1997.10.27 US 60/063,644|1998.08.24 US 097,685

False: 1997.10.27 US 60/063,644

Number: 7

Page: The title page

Volume: 20

COR Change of bibliographic data

Free format text: CORRECT: PRIORITY; FROM: 1997.10.27 US 60/063,644 TO: 1997.10.27 US 60/063,644 1998.8.24 US 097,685

ERR Gazette correction

Free format text: CORRECT: PRIORITY; FROM: 1997.10.27 US 60/063,644 TO: 1997.10.27 US 60/063,644 1998.8.24 US 097,685

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1030768

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040218

Termination date: 20130923